Retrophin Received its Third Buy in a Row

By Carrie Williams

After BMO Capital and JMP Securities assigned a Buy rating to Retrophin in the last month, the company received another Buy, this time from Leerink Swann. Analyst Joseph Schwartz reiterated a Buy rating on Retrophin (NASDAQ: RTRX) yesterday and set a price target of $30. The company’s shares opened today at $18.93.

According to, Schwartz is a 5-star analyst with an average return of 9.8% and a 46.5% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as DBV Technologies S.A. – American, Proteostasis Therapeutics Inc, and Achillion Pharmaceuticals.

Currently, the analyst consensus on Retrophin is Strong Buy and the average price target is $35, representing an 84.9% upside.

In a report issued on November 3, BMO Capital also reiterated a Buy rating on the stock with a $40 price target.

Based on Retrophin’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $33.95 million and GAAP net loss of -$37,113,000. In comparison, last year the company earned revenue of $28.01 million and had a net profit of $106 million.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RTRX in relation to earlier this year. Most recently, in March 2016, Jeffrey Meckler, a Director at RTRX bought 5,000 shares for a total of $76,550.

Retrophin, Inc. is a fully integrated biopharmaceutical company, which develops pharmaceutical products for the treatment of rare diseases. It is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.